Related Experiment Video
Updated: May 22, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Current antiplatelet options for NSTE-ACS patients
G Cayla1, J Silvain, S A O'Connor
1Institut de Cardiologie, Bureau 236, Pitié-Salpêtrière University Hospital, 47-83, Bld de l'Hôpital, 75013 Paris, France.
Summary
Newer antiplatelet drugs, ticagrelor and prasugrel, show greater effectiveness than clopidogrel for non-ST-elevation acute coronary syndrome (NSTE-ACS). These agents offer improved patient outcomes with manageable bleeding risks, aiding personalized treatment strategies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Non-ST-elevation acute coronary syndrome (NSTE-ACS) is a common cardiovascular condition.
- Platelet activation is a key factor in NSTE-ACS pathogenesis.
- Dual antiplatelet therapy (DAPT) with aspirin is a standard treatment.
Purpose of the Study:
- To review drugs used with aspirin for DAPT in NSTE-ACS.
- To compare the efficacy and safety of clopidogrel, ticagrelor, and prasugrel.
- To guide individualized treatment selection for NSTE-ACS patients.
Main Methods:
- Literature review of clinical studies on antiplatelet therapies in NSTE-ACS.
- Analysis of comparative effectiveness and safety data for clopidogrel, ticagrelor, and prasugrel.
- Evaluation of factors influencing treatment outcomes, including patient comorbidities.
Main Results:
- Ticagrelor and prasugrel are more effective than clopidogrel in NSTE-ACS patients.
- These newer agents demonstrate acceptable tolerability and manageable bleeding risks.
- Differences between ticagrelor and prasugrel suggest potential for tailored therapy.
Conclusions:
- Ticagrelor and prasugrel represent advances over clopidogrel for NSTE-ACS.
- Further head-to-head trials are needed to directly compare ticagrelor and prasugrel.
- Individualizing NSTE-ACS treatment based on drug profiles can reduce morbidity and mortality.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...